Caribou says partial HLA matching will improve durability of response to cell therapy

Lei Lei Wu

News Reporter

CHICAGO — Caribou’s off-the-shelf cell therapy appears poised to break free from the rapid relapses that have plagued other off-the-shelf cell therapies, according to a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Caribou says partial HLA matching will improve durability of response to cell therapy

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Biogen gets $250M in Royalty Pharma deal for Phase 3 lupus program

AbbVie pens another T cell engager deal, this time with Xilio

Exclusive: Longevity startup targets renegade proteins linked to diabetes and obesity

After passing on M&A offers, Abcuro raises $200M in bid to become commercial drugmaker

Biogen downplays capacity for M&A; Roche’s SMA drug is approved as a tablet

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

Cari­bou says par­tial HLA match­ing will im­prove dura­bil­i­ty of re­sponse to cell ther­a­py

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Caribou says partial HLA matching will improve durability of response to cell therapy